27 minutes ago | San Diego Biotechnology
Selling a combination of consulting services and technical product solutions in biotech, cell and gene therapy markets. Global VP Commercial .From Fortive - Tue, 10 Dec 2019...
Read more ...
47 minutes ago | BMC Bioinformatics
Although targeted drugs have contributed to impressive advances in the treatment of cancer patients, their clinical benefits on tumor therapies are greatly limited due to...
Read more ...
4 hours ago | Xconomy
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat...
Read more ...
4 hours ago | San Diego Biotechnology | 3 articles
Fate Therapeutics:
seeks experienced, motivated cell therapy process development engineer to lead scale-up and cGMP-compliant PD for new cellular immunotherapeutics 92121, San...
Read more ...
8 hours ago | Xconomy
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other...
Read more ...
13 hours ago | San Diego Biotechnology | 3 articles
AveXis Inc.:
OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene
San Diego...
Read more ...
13 hours ago | San Diego Biotechnology | 3 articles
AveXis Inc.:
OverviewReady to join a team committed to moving gene therapies into the clinical and commercial settings for patients and families devastated by rare
San Diego...
Read more ...
19 hours ago | Xconomy
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions...
Read more ...
1 day ago | Springer | 2 articles
Abstract
Background
Although targeted drugs have contributed to impressive advances in the treatment of cancer patients, their clinical benefits on tumor therapies are greatly...
Read more ...
1 day ago | Springer | 2 articles
Abstract
With the first RNA interference drug ) on the market, we witness the RNAi therapy field reaching a critical turning point, when further improvements in drug candidate...
Read more ...
Register you to post on BioTech Mag
Free Registration
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...
Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...
Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...
The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...
LA JOLLA-In mouse models of Alzheimer's disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk... Read more ...